Clinical Trial Search

Primary: Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period — NA; NA days — p=<0.001

Primary: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 92.9; 7.1 percentage of participants

Primary: Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15 — 0.69; 0.10 g/m^2 — p=0.8811

Primary: Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb and Within Target Range During the Efficacy Evaluation Period (EEP)…

Primary: Number of Patients With Adverse Events, Serious Adverse Events, and Death — 26; 25; 24; 139 Number of Patients

Primary: Number of Participants With an Absence of Anterior Chamber Inflammation — 63; 25 participants

Primary: Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score — -10.2 Units on a scale — p=<0.0001

Primary: Change From Baseline to Week 6 in PANSS Total Score — -15.9; -20.0; -24.0 units on a scale — p=0.0560

Primary: Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score — -18.1 Units on a scale — p=<0.0001

Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -19.6 Units on a scale — p=<0.0001

Primary: Percent Change From Baseline in Inflammatory Lesions — 79.87; 80.86; 45.60 percentage of lesion reduction — p=0.05

Primary: Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period. — -8.8; -1.3 mmHg — p=<0.0001

Primary: Number of Seroconverted Subjects for Anti-HPV-16/18 Antibodies as Assessed by Enzyme-Linked Immunosorbent Assay (ELISA) at Month 7 Based on the ATP Cohort for…

Primary: Composite Daily Score — 6.9; 9.7 units on a scale

Primary: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) — 267; 260; 235; 206 Participants